TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7490909
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment for 4 months
Study: 2253528
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous bolus dose of edrophonium
Study: 2253528
Drug: 80 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 micrograms/kg intravenous bolus dose of edrophonium
Study: 2253528
Drug: saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline placebo injections
Study: 6986027
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg every six hours)
Study: 7406571
Drug: Antacids (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids (average requirement 41 cc/hour)
Study: 7406571
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (cimetidine and antacids)
Study: 27920018
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,200 mg single dose
Study: 25697217
Drug: Overall CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall CC patients
Study: 23703408
Drug: Transforaminal balloon
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal balloon treatment with a Fogarty balloon catheter (n = 32)
Study: 19650752
Drug: Alogliptin 12.5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg
Study: 18405788
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg
Study: 8787880
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g every 8 h (q8h) bolus dosing (BD)
Study: 8787880
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g every 12 h (q12h) bolus dosing (BD)
Study: 3537288
Drug: Dimethicone-containing antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethicone-containing antacid gel (Asilone Gel)
Study: 3537288
Drug: Simple antacid
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple antacid gel
Study: 29417463
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination tablet of sofosbuvir and ledipasvir (400/90 mg)
Study: 19042044
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no atorvastatin)
Study: 16628033
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (2.0 mL/kg of 300 mgI/mL contrast medium, injection duration 30 seconds, mean rate 3.6 mL/sec)
Study: 16628033
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (2.0 mL/kg of 300 mgI/mL contrast medium, injection duration 25 seconds, mean rate 4.6 mL/sec)
Study: 16628033
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (2.0 mL/kg of 300 mgI/mL contrast medium, injection duration 30 seconds, mean rate 3.6 mL/sec followed by saline chaser)
Study: 10825333
Drug: Ketamine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.4 mg/kg IV before skin incision
Study: 1524140
Drug: Bovine immunoglobulin
Normalized name: Bovine immunoglobulin concentrate, cryptosporidium parvum
DrugBank: Cryptosporidium immune globulin (DB17785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine immunoglobulin concentrate with high titer of anti-S. flexneri 2a LPS, administered three times a day for seven days.
Study: 30302881
Drug: L-Dcau group
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dcau group (1 mL/kg of caudal 0.25% levobupivacaine plus 1 μg/kg dexmedetomidine and IV 20 mL saline)
Study: 30302881
Drug: L-Div group
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Div group (1 mL/kg of caudal 0.25% levobupivacaine and IV 1 μg/kg dexmedetomidine in 20 mL saline)
Study: 30302881
Drug: L group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L group (1 mL/kg of caudal 0.25% levobupivacaine and IV 20 mL saline)
Study: 25032872
Drug: 13-valent conjugated
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent conjugated vaccine
Study: 25032872
Drug: 23-polysaccharide vaccine
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-polysaccharide vaccine
Study: 25032872
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (13-valent conjugated and 23-polysaccharide)
Study: 20160157
Drug: Linagliptin 2.5
Normalized name: linagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 2.5 mg (28 days)
Study: 20160157
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg (28 days)
Study: 28746738
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education programme focusing on developing emotional knowledge skills around daily health habits (eating, hygiene, sleep, and physical exercise) using game-based dynamics and an emotional diary.
Study: 27521377
Drug: Group reminiscence
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group reminiscence therapy (RYCT)
Study: 20684665
Drug: DHEP heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP heparin plaster
Study: 18671909
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTA) injection plus ankle‐foot casting (n=6)
Study: 7769193
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 micrograms q.i.d. for 13 doses) during indomethacin treatment (50 mg p.o. t.i.d. for 10 doses)
Study: 7769193
Drug: Misoprostol treatment
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol treatment only
Study: 2320783
Drug: Borg's scale
Approvals — FDA: no, EMA: no, PMDA: no
Description: Borg's scale dyspnoea level greater than 5 and peak flow less than 150 l/min
Study: 19617879
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of pidolate Mg(2+) daily for 12 weeks
Study: 2741218
Drug: CAP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP regimen (cyclophosphamide 200 mg/m2 i.v. days 1, 3 and 5, adriamycin 40 mg/m2 i.v. day 1, platinum 30 mg/m2 i.v. day 1, 3 and 5)
Study: 31216826
Drug: Adjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant concurrent chemo-radiotherapy (more than 5 weeks)
Study: 31216826
Drug: Adjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant concurrent chemo-radiotherapy
Study: 25988769
Drug: Polaprezinc (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (34 mg/day of zinc)
Study: 17202560
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg/day)
Study: 10619583
Drug: losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan (50 mg)
Study: 10619583
Drug: valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan (80 mg)
Study: 17598639
Drug: eprosartan (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: eprosartan (600 mg)
Study: 9990214
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin 5 mg
Study: 25959002
Drug: Oral chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chemotherapy
Study: 29406853
Drug: Ticagrelor (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (60 mg and 90 mg)
Study: 29649055
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg twice daily
Study: 26222126
Drug: EPA-E 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-E 1.8 g/day
Study: 18245013
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment for screen‐diagnosed lung cancer
Study: 12934464
Drug: Current methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current methods of OP prevention and treatment
Study: 10868643
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (250 mg i.v. methylprednisolone at 1 and 6 hr)
Study: 10868643
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (500 mg i.v. methylprednisolone at 1 hr before initial OKT3)
Study: 10868643
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (Atgam 15 mg/kg on day 0, OKT3 on day 1)
Study: 9195083
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg once daily for 14 days)
Study: 29745884
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 4 and 8 mg/kg in combination with methotrexate (MTX)
Study: 30253197
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg escitalopram
Study: 12597081
Drug: Euglycemia (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (4.5 mmol/L)
Study: 10910840
Drug: d‐tubocurarine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine 3 mg followed by succinylcholine 1.5 mg/kg
Study: 8610912
Drug: mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.2 mg/kg
Study: 8659780
Drug: Lidocaine (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1, 3, and 6 mg.min(‐1))
Study: 8659780
Drug: Bupivacaine (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.25, 0.75, and 1.5 mg.min(‐1))
Study: 3620276
Drug: Isoxicam (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoxicam (300 mg day-1)
Study: 3620276
Drug: Piroxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (40 mg day-1 for the first two days and 20 mg day-1 for the remaining days)
Study: 31444972
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with bevacizumab
Study: 28487444
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone in estrogen receptor-positive patients
Study: 23819631
Drug: ACE-inhibitor (ramipril)
Normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor (ramipril)
Study: 21078948
Drug: BMS-488043 (AI)
Normalized name: BMS dasatinib
DrugBank: BMS-488043 (DB05532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-488043 (AI) administered as monotherapy for 8 days
Study: 19506159
Drug: Dose-dense temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose-dense temozolomide (150 mg/m² days 1 to 7 and 15 to 21)
Study: 19506159
Drug: Metronomic temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic temozolomide (50 mg/m² continuous daily)
Study: 15055895
Drug: 16-G cannula
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-G cannula with local anaesthesia
Study: 15055895
Drug: 14-G cannula
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14-G cannula without local anaesthesia
Study: 15055895
Drug: 16-G cannula
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-G cannula without local anaesthesia
Study: 2929966
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg by mouth the evening prior to surgery and 150 mg by mouth before the operation)
Study: 2929966
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (30 ml shortly before admission to the operating room)
Study: 30559004
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous (IV) infusion of LCB01-0371 at doses of 200, 400, 800, and 1200 mg
Study: 30559004
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of LCB01-0371 at a dose of 800 mg
Study: 30559004
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous (IV) administration of LCB01-0371 at a dose of 400 mg
Study: 30559004
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous (IV) administration of LCB01-0371
Study: 28499730
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with silodosin 8 mg per day and dutasteride 0.5 mg per day for 12 months
Study: 28499730
Drug: Dutasteride monotherapy
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride monotherapy after silodosin withdrawal
Study: 16397284
Drug: Lasofoxifene 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene 0.03 mg
Study: 16397284
Drug: Lasofoxifene 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene 0.1 mg
Study: 16397284
Drug: Lasofoxifene 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene 0.3 mg
Study: 16397284
Drug: Lasofoxifene 1
Normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Lasofoxifene 1 mg
Study: 12507747
Drug: Olanzapine 5-20
Normalized name: olanzapine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5-20 mg daily
Study: 8364262
Drug: MEMS (electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEMS (electronic medication-event monitoring device)
Study: 8364262
Drug: Pill counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill counts (control group)
Study: 8364262
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pill counts)
Study: 2878088
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B administered intravenously in small doses
Study: 29548345
Drug: Volixibat 20
Normalized name: Volixibat
DrugBank: Volixibat (DB13914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volixibat 20 mg, 40 mg, or 80 mg once daily for 12 days
Study: 27634451
Drug: Ultrasound-guided supraclavicular
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided supraclavicular phrenic nerve block with 10 ml ropivacaine
Study: 22964540
Drug: Guided Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-based psychodynamic treatment (IPDT)
Study: 22964540
Drug: Guided Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-based cognitive behavior therapy (ICBT)
Study: 23566649
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg daily)
Study: 14728495
Drug: Current IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current IV infusion pump systems without intelligent software
Study: 6402355
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg sustained release isosorbide dinitrate
Study: 6666220
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isosorbide‐5‐mononitrate
Study: 27028745
Drug: Kikyo-To (KKT)
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kikyo-To (KKT) 5.0 g mixed with jelly
Study: 11505880
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dexamethasone
Study: 7752655
Drug: Cicletanine 50
Normalized name: cicletanine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 50 mg daily (group I)
Study: 7752655
Drug: Cicletanine 50
Normalized name: cicletanine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 50 mg daily (group II)
Study: 7752655
Drug: Cicletanine 100
Normalized name: cicletanine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 100 mg daily (group III)
Study: 7286055
Drug: Anhydrous crystalline
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anhydrous crystalline theophylline 250 mg (rectal administration)
Study: 7286055
Drug: Microcrystalline theophylline
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline theophylline 250 mg (oral administration)
Study: 29934056
Drug: Fidaxomicin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidaxomicin (200 mg twice daily, orally)
Study: 29934056
Drug: Vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (125 mg four-times daily, orally)
Study: 25237481
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment orders (CTOs)
Study: 22884569
Drug: Immediately Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately Sequential Bilateral Cataract Surgery (ISBCS)
Study: 19396775
Drug: Oxybiane (antioxidants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybiane (antioxidants combination)
Study: 15309206
Drug: Angiogenic growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiogenic growth factors (e.g., vascular endothelial growth factors, fibroblast growth factor)
Study: 9627295
Drug: Dexamethasone (0.37
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.37 mg/d) for 1 year
Study: 3661644
Drug: Intravitreal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal blood (12.5 microliter of blood in the 5-ml test chamber)
Study: 2142013
Drug: Inhaled PAF
Normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled PAF (3-422 micrograms)
Study: 2142013
Drug: GR32191B (thromboxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191B (thromboxane receptor antagonist)
Study: 644461
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with bacillus Calmette‐Guerin (BCG)
Study: 31896155
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (T2DM-adapted diet)
Study: 31896155
Drug: Oatmeal treatment
Normalized name: OATMEAL 5 g in 100 mL TOPICAL SOLUTION [Quick Relief Colloidal Oatmeal Treatment for face, eyes and body]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oatmeal treatment for 2 days
Study: 31447123
Drug: Galvanic current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galvanic current with base gel solution on both electrodes.
Study: 28419032
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol for physical therapy (in-home visits for 2 weeks followed by outpatient therapy for 8 weeks)
Study: 21810227
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (3 cycles of ECC: epirubicin, cisplatin, and capecitabine) followed by surgery and either postoperative chemotherapy (3 cycles of ECC) or concurrent chemoradiotherapy (45 Gy, cisplatin, and capecitabine)
Study: 11429341
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow (FGF) at 2 L/min
Study: 8070511
Drug: 60 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 micrograms of prostaglandin E1 (PGE1) administered by intravenous infusion
Study: 26476267
Drug: Cognitive-Behavioral-Based Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral-Based Physical Therapy (CBPT)
Study: 23356247
Drug: High-dose ω-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ω-3 fatty acid ethyl esters (3.2 g/day)
Study: 8071277
Drug: Nefazodone 100-500
Normalized name: nefazodone
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nefazodone 100-500 mg/day
Study: 8071277
Drug: Nefazodone 50-250
Normalized name: nefazodone
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nefazodone 50-250 mg/day
Study: 8071277
Drug: Imipramine 50-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 50-250 mg/day
Study: 3289961
Drug: Methylcholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcholine inhalation
Study: 26628263
Drug: Ischemic compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ischemic compression via physical therapy (administered three times for 60 seconds each with 30 seconds rest)
Study: 21445092
Drug: Degarelix (s.c.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (s.c., 240/80 mg, n=207)
Study: 21445092
Drug: Degarelix (s.c.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (s.c., 240/160 mg, n=202)
Study: 11028723
Drug: IT tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IT tetracaine 15 mg + neostigmine 50 microg
Study: 11028723
Drug: IT tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IT tetracaine 15 mg + neostigmine 100 microg
Study: 11028723
Drug: IT tetracaine
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IT tetracaine 15 mg
Study: 8452169
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once a day for 7 days